Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02510261 · ClinicalTrials.gov registry record · Phase 3
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
A Phase 3 study of Amyloidosis, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
- 20
- Study locations
NCT02510261 is a Phase 3 study of Amyloidosis that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 211 participants, below the 1,121-participant average among 28 other Amyloidosis trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02510261, a Phase 3 study of Amyloidosis, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
Conditions Studied
Interventions
- DRUG Patisiran
Study Locations (20)
Other
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Westmead
- Clinical Trial Site - Rio de Janeiro
- Clinical Trial Site - São Paulo
- Clinical Trial Site - Sofia
New York
- Clinical Trial Site - Cooperstown
- Clinical Trial Site - New York
- Clinical Trial Site - New York
Missouri
- Clinical Trial Site - Joplin
- Clinical Trial Site - St Louis
California
- Clinical Trial Site - La Mesa
Colorado
- Clinical Trial Site - Aurora
Florida
- Clinical Trial Site - Jacksonville
Illinois
- Clinical Trial Site - Chicago
Maryland
- Clinical Trial Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2015-07-16 |
| Est. Completion | 2022-11-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02510261
The ClinicalTrials.gov registry entry for NCT02510261 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,121-participant average among 28 other Amyloidosis trials with a reported enrollment target (81% lower). The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Patisiran is the first listed.
NCT02510261 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, New York, Missouri.
Frequently Asked Questions
What is clinical trial NCT02510261 about?
NCT02510261 is a clinical study titled "The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)". The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
What is the current status of trial NCT02510261?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2015-07-16. Estimated completion is 2022-11-23.
What conditions does trial NCT02510261 study?
This clinical trial studies the following conditions: Amyloidosis.
What interventions are being tested in trial NCT02510261?
The interventions under investigation include: Patisiran (DRUG).
Who is sponsoring clinical trial NCT02510261?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02510261 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
COMPLETED · Phase 3
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
-
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
RECRUITING
-
Dietary Reporting in the Amyloidoses
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.